BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 30321467)

  • 1. Efficacy of therapeutic plasma exchange on angiotensin II type-1 receptor antibodies on two kidney transplant recipients.
    Yamada C; Huang Y; Norman S; Naik A; Moussa O; Samaniego M; Cooling L
    J Clin Apher; 2018 Dec; 33(6):673-677. PubMed ID: 30321467
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Angiotensin II type-1 receptor antibody (AT1Rab) associated humoral rejection and the effect of peri operative plasma exchange and candesartan.
    Carroll RP; Riceman M; Hope CM; Zeng A; Deayton S; Bennett GD; Coates PT
    Hum Immunol; 2016 Dec; 77(12):1154-1158. PubMed ID: 27542526
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pretransplant angiotensin II type 1-receptor antibodies are a risk factor for earlier detection of de novo HLA donor-specific antibodies.
    Cuevas E; Arreola-Guerra JM; Hernández-Méndez EA; Salcedo I; Castelán N; Uribe-Uribe NO; Vilatobá M; Contreras-Saldívar AG; Sánchez-Cedillo AI; Ramírez JB; de Rungs D; Granados J; Morales-Buenrostro LE; Alberú J
    Nephrol Dial Transplant; 2016 Oct; 31(10):1738-45. PubMed ID: 27220757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of plasmapheresis on donor-specific antibody reduction by HLA specificity in post-kidney transplant recipients.
    Yamada C; Ramon DS; Cascalho M; Sung RS; Leichtman AB; Samaniego M; Davenport RD
    Transfusion; 2015 Apr; 55(4):727-35; quiz 726. PubMed ID: 25385678
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pretransplant angiotensin II type 1-receptor antibodies point to an increase in renal graft sub-intimal fibrosis in living- donor kidney transplant recipients.
    González-Almada A; Arreola-Guerra JM; López-Sánchez JA; Cuevas E; Vilatoba M; Contreras AG; Morales-Buenrostro LE; Alberu J; Uribe-Uribe NO
    Transpl Immunol; 2019 Jun; 54():1-8. PubMed ID: 30336216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pre-transplant angiotensin II type 1receptor antibodies: a risk factor for decreased kidney graft function in the early post-transplant period?
    Hernández-Méndez EA; Arreola-Guerra JM; Morales-Buenrostro LE; Ramírez JB; Calleja S; Castelán N; Salcedo I; Vilatobá M; Contreras AG; Gabilondo B; Granados J; Alberú J
    Rev Invest Clin; 2014; 66(3):218-24. PubMed ID: 25695237
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pre-transplant angiotensin II type 1 receptor antibodies: A risk factor for decreased kidney graft function in the early post-transplant period?
    Hernández-Méndez EA; Arreola-Guerra JM; Morales-Buenrostro LE; Ramírez JB; Calleja S; Castelán N; Salcedo I; Vilatobá M; Contreras AG; Gabilondo B; Granados J; Alberú J
    Clin Transpl; 2013; ():343-50. PubMed ID: 25095527
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of Biopsy-Proven Acute Antibody-Mediated Rejection Using Thymoglobulin (ATG) Monotherapy and a Combination of Rituximab, Intravenous Immunoglobulin, and Plasmapheresis: Lesson Learned from Primary Experience.
    Zheng J; Xue W; Qing X; Jing X; Hou J; Tian X; Guo Q; He X; Cai J
    Clin Transpl; 2014; ():223-30. PubMed ID: 26281149
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Investigation of Serum Angiotensin II Type 1 Receptor Antibodies at the Time of Renal Allograft Rejection.
    Lee H; Kim JI; Moon IS; Chung BH; Yang CW; Kim Y; Han K; Oh EJ
    Ann Lab Med; 2015 May; 35(3):314-20. PubMed ID: 25932439
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcome of Pretransplantation Therapeutic Plasma Exchange in Highly Sensitized Deceased-donor Kidney Transplant Recipients.
    Tipjaiaue P; Ingsathit A; Kantachuvesiri P; Rattanasiri S; Thammanichanond D; Mongkolsuk T; Arpornsujaritkun N; Sumethkul V; Kantachuvesiri S
    Transplant Proc; 2017; 49(6):1249-1255. PubMed ID: 28735989
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The influence of non-HLA antibodies directed against angiotensin II type 1 receptor (AT1R) on early renal transplant outcomes.
    Banasik M; Boratyńska M; Kościelska-Kasprzak K; Kamińska D; Bartoszek D; Zabińska M; Myszka M; Zmonarski S; Protasiewicz M; Nowakowska B; Hałoń A; Chudoba P; Klinger M
    Transpl Int; 2014 Oct; 27(10):1029-38. PubMed ID: 24909812
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Presentation and Outcomes of Antibody-Mediated Rejection Associated With Angiotensin II Receptor 1 Antibodies Among Kidney Transplant Recipients.
    Abuzeineh M; Kyeso Y; Philogene MC; Alachkar N; Alasfar S
    Transplant Proc; 2021 Jun; 53(5):1501-1508. PubMed ID: 33573814
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Impact of Pre-transplant Antibodies Against Angiotensin II Type I Receptor and Major Histocompatibility Complex Class I-Related Chain A in Kidney Transplant Patients.
    Min JW; Lee H; Choi BS; Park CW; Yang CW; Kim YS; Choi YJ; Oh EJ; Chung BH
    Ann Lab Med; 2018 Sep; 38(5):450-457. PubMed ID: 29797816
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination of Total Lymphoid Irradiation, Low-Dose IVIG and ATG as Rescue Therapy for Highly Sensitized and Antibody-Mediated Rejection Renal Transplant Recipients.
    Zhu D; Qi G; Tang Q; Li L; Yang C; Lin M; Wu B; Xu M; Cai J; Zhu T; Rong R
    Clin Transpl; 2014; ():215-21. PubMed ID: 26281148
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical implications of angiotensin II type 1 receptor antibodies in antibody-mediated rejection without detectable donor-specific HLA antibodies after renal transplantation.
    Lee J; Park Y; Kim BS; Lee JG; Kim HJ; Kim YS; Huh KH
    Transplant Proc; 2015 Apr; 47(3):649-52. PubMed ID: 25891704
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute kidney transplant rejection mediated by angiotensin II type 1 receptor antibodies in a pediatric hyperimmune patient.
    Guzzo I; Morolli F; Camassei FD; Piazza A; Poggi E; Dello Strologo L
    Pediatr Nephrol; 2017 Jan; 32(1):185-188. PubMed ID: 27752765
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibody-Mediated Rejection in Kidney Transplantation Without Evidence of Anti-HLA Antibodies?
    Irure J; López-Hoyos M; Rodrigo E; Gómez-Román J; Ruiz JC; Arias M; San Segundo D
    Transplant Proc; 2016 Nov; 48(9):2888-2890. PubMed ID: 27932099
    [TBL] [Abstract][Full Text] [Related]  

  • 18. C4d-negative antibody-mediated rejection with high anti-angiotensin II type I receptor antibodies in absence of donor-specific antibodies.
    Fuss A; Hope CM; Deayton S; Bennett GD; Holdsworth R; Carroll RP; Coates PT
    Nephrology (Carlton); 2015 Jul; 20(7):467-73. PubMed ID: 25726938
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Measurement of donor-specific HLA antibodies following plasma exchange therapy predicts clinical outcome in pediatric heart and lung transplant recipients with antibody-mediated rejection.
    Jackups R; Canter C; Sweet SC; Mohanakumar T; Morris GP
    J Clin Apher; 2013 Aug; 28(4):301-8. PubMed ID: 23426730
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A refractory case of subclinical antibody-mediated rejection due to anti-HLA-DQ antibody in a kidney transplant patient.
    Fujimoto T; Nakada Y; Yamamoto I; Kobayashi A; Tanno Y; Yamada H; Miki J; Ohkido I; Tsuboi N; Yamamoto H; Yokoo T
    Nephrology (Carlton); 2015 Jul; 20 Suppl 2():81-5. PubMed ID: 26031594
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.